TCGA-BH-A0AV-01A-31R-A115-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
- TGF_BETA_SIGNALING+0.540
- G2M_CHECKPOINT+0.440
- E2F_TARGETS+0.430
- HYPOXIA+0.430
- UV_RESPONSE_DN+0.420
- HEDGEHOG_SIGNALING+0.410
- MITOTIC_SPINDLE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.360
- APICAL_JUNCTION+0.350
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- FATTY_ACID_METABOLISM-0.320
- INTERFERON_ALPHA_RESPONSE-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
- BILE_ACID_METABOLISM-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- PEROXISOME-0.230
- ADIPOGENESIS-0.220
- ESTROGEN_RESPONSE_LATE-0.200
- DNA_REPAIR-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168609 | — | — | 0.873 |
| 2 | 20140163.TNBC | — | D | 0.852 |
| 3 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.842 |
| 4 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.836 |
| 5 | TCGA-AR-A24Q-01A-12R-A169-07 | — | E | 0.830 |
| 6 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.827 |
| 7 | TCGA-A7-A6VV-01A-22R-A33J-07 | — | E | 0.826 |
| 8 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.823 |
| 9 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.823 |
| 10 | TCGA-BL-A5ZZ-01A-31R-A30C-07 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.620 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |